Michel AguetDr. Michel Aguet, MD, held positions in academia and industry (Associate Professor at the Institute of Molecular Biology, University of Zürich; Head of Molecular Oncology, Genentech, So. San Francisco) before he was appointed director of the Swiss Institute for Experimental Cancer Research (ISREC) (1996-2009). In the context of the integration of ISREC into the Swiss Federal Institute of Technology (EPFL), he was appointed as Full Professor at the newly established School of Life Sciences in 2005. From 2001-2013 he directed the National Center of Competence in Research (NCCR) in Molecular Oncology, a national program launched by the Swiss National Science Foundation to encourage translational cancer research and for which ISREC was the leading house. Dr. Aguet has been a SAB member in the pharmaceutical industry, biotech industry and venture capital industry since 1997.
A large part of his scientific career was devoted to exploring the molecular biology of interferons (cloning of the interferon gamma receptor, generation of various interferon signaling mutants in the mouse) and, in collaboration with Prof. Charles Weissmann, to investigating the role of prion related protein PrP in mouse prion disease models. In recent years his research focused on characterizing the role of BCL9 proteins, which are part of the Wnt/beta-catenin transcriptional activation complex, in regulating stem cell traits in intestinal epithelium and colorectal cancer. His laboratory is now closed due to retirement.
Stewart ColeProfessor Stewart Cole is an international authority in bacterial molecular-genetics and genomics. He has made outstanding contributions in several fields including: bacterial anaerobic electron transport; genome analysis of retroviruses and papillomaviruses; antibiotic resistance mechanisms; and the molecular microbiology of toxigenic clostridia. His studies on isoniazid and multidrug resistance in Mycobacterium tuberculosis, together with his pioneering work on the pathogenicity, evolution and genomics of the tubercle and leprosy bacilli, have made him an undisputed leader in the field of mycobacterial research. The findings of his research are of direct relevance to public health and disease-control in both the developing world and the industrialised nations. He has published over 250 scientific papers and review articles, and holds many patents.
Olivier MartinOlivier J.F. Martin a obtenu le diplôme (M.Sc.) et le doctorat en physique de l'Ecole Polytechnique Fédérale de Lausanne (EPFL) en 1989, respectivement 1994. En 1989 il a rejoint le laboratoire de recherche d'IBM à Rüschlikon près de Zurich, où il a étudié les propriétés optiques et thermiques des lasers semiconducteur. Entre 1994 et 1997 il était collaborateur scientifique de l'Ecole Polytechnique Fédérale de Zurich (ETHZ). En 1997 il a reçu une bourse Profil du Fonds National Suisse de la Recherche Scientifique (FNSRS) lui permettant de mettre sur pied un groupe de recherche indépendant. Entre 1996 et 1999, Olivier Martin a passé plus d'une année et demi aux U.S.A. comme collaborateur invité de l'Université de Californie à San Diego. En 2001 il a reçu une bourse de professeur assistant du FNSRS et devint professeur de Nano-optique à l'ETHZ. En 2003 il a été nommé professeur de nanophotonique et de traitement optique du signal à l'EPFL où il dirige actuellement le laboratoire de Nanophotonique & Métrologie.
